MedTrace Logo

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

NCT02380079 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-03-21

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.

Conditions

Interventions

DRUG

SCD-101

Administered as gelatin capsules

Sponsors & Collaborators

  • State University of New York - Downstate Medical Center

    collaborator OTHER

  • Invenux, LLC

    lead INDUSTRY

Principal Investigators

  • John Muthu, MD · King's County Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2023-11-30
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02380079 on ClinicalTrials.gov